Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for verifying reason for promoting HCC chemotherapy drug resistance by regulating PTEN-AKT signal axis through UBE2S

A technology of PTEN-AKT and verification method, which is applied in the direction of biochemical equipment and methods, microbial measurement/testing, material inspection products, etc., to achieve the effect of improving curative effect, promoting the formation of chemotherapy resistance, and improving prognosis

Pending Publication Date: 2022-05-31
桂亮
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few studies on the relationship between UBE2S and liver cancer chemotherapy resistance. Therefore, we intend to explore the mechanism of UBE2S in liver cancer chemotherapy resistance and verify it so that relevant researchers can find ways to reverse HCC chemotherapy resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for verifying reason for promoting HCC chemotherapy drug resistance by regulating PTEN-AKT signal axis through UBE2S
  • Method for verifying reason for promoting HCC chemotherapy drug resistance by regulating PTEN-AKT signal axis through UBE2S
  • Method for verifying reason for promoting HCC chemotherapy drug resistance by regulating PTEN-AKT signal axis through UBE2S

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0060] In order to better understand the technical content of the present invention, specific embodiments are given and described in conjunction with the accompanying drawings as follows.

[0061] Aspects of the invention are described in this disclosure with reference to the accompanying drawings, in which a number of illustrative embodiments are shown.

Embodiments of the present disclosure are not necessarily intended to include all aspects of the invention. It should be understood that the various concepts and implementations described above

[0063] Currently, the role of each member in E2 is unclear. We screened for ubiquitination using bioinformatics analysis

This is because the concepts and embodiments disclosed herein are not limited to any implementation. In addition, the present invention discloses

Some aspects may be used alone or in any suitable combination with other aspects disclosed herein.

Previous studies have shown that ubiquitination modification and u...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for verifying reasons for promoting HCC chemotherapy drug resistance by using UBE2S to regulate a PTEN-AKT signal axis. The method comprises the following processes: verifying a relationship between UBE2S in HCC and a drug-resistant pathway, silencing UBE2S in HCC cells, and verifying UBE2S and the drug-resistant pathway by using an RNA-seq technology and gene enrichment analysis; the drug resistance of UBE2S expression in the HCC cells to fluorouracil and oxaliplatin is verified; the correlation between the transcription factor FOXM1 and UBE2S expression is verified; fOXM1-UBE2S downstream molecules and the regulation and control effect thereof, in-vivo experiments and in-vitro experiments are verified. The invention verifies that abnormal high expression of UBE2S exists in chemotherapy-resistant HCC cells, and influences on chemotherapy resistance by promoting PTEN ubiquitination, reducing the PTEN protein expression level and regulating and controlling a PI3K-AKT signal axis are achieved. UBE2S is taken as an HCC chemotherapy curative effect prediction index, the potential of a new drug-resistant target is reversed, and related researchers are facilitated to improve the curative effect and improve the prognosis of patients by overcoming HCC chemotherapy drug resistance.

Description

Validation method of UBE2S regulating the PTEN‑AKT signaling axis to promote the cause of chemotherapy resistance in HCC technical field The present invention relates to the field of HCC treatment, specifically UBE2S regulates PTEN-AKT signal axis to promote HCC chemotherapeutic drug resistance method of verification. Background technique Hepatocellular carcinoma (HCC) is the most common pathological type in primary liver cancer, with insidious onset and high invasiveness Most patients have advanced disease at the time of diagnosis. The current overall treatment effect of HCC is not satisfactory, even after receiving In patients with radical surgery, the 5-year recurrence rate is still as high as 70%, the 5-year overall survival rate is less than 20%, and systemic therapy is late. It is the main treatment method for patients with stage and recurrent HCC. In recent years, although immunotherapy has made great breakthroughs in liver cancer, immune The efficacy of si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574G01N33/68
CPCC12Q1/6886G01N33/57438G01N33/68C12Q2600/158C12Q2600/106
Inventor 桂亮朱滢章思偲徐永子
Owner 桂亮
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products